Landman David, Cherniak Meir, Gefen Orit, Michael-Gayego Ayelet, Motro Yair, Moran-Gilad Jacob, Strahilevitz Jacob
Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University, Jerusalem 91120, Israel.
Racah Institute of Physics, The Hebrew University of Jerusalem, Jerusalem, Israel.
J Antimicrob Chemother. 2025 Jun 3;80(6):1519-1525. doi: 10.1093/jac/dkaf095.
Enterococcus gallinarum and Enterococcus casseliflavus are increasingly identified as causes of healthcare-associated infections. Although hepatobiliary infection and catheter-related bloodstream infection predominate, endovascular infection can also occur. The optimal treatment of these infections is unknown.
To determine the in vitro activity of ampicillin, gentamicin and ceftriaxone against clinical isolates of E. gallinarum and E. casseliflavus.
Bloodstream isolates of E. gallinarum (n = 10) and E. casseliflavus (n = 8) were collected from unique patients between 2008 and 2022 at one institution. The activity of ampicillin was tested alone and combined with gentamicin and ceftriaxone by the time-kill method.
All isolates were susceptible to ampicillin and none had gentamicin MIC > 128 mg/L. At concentrations of 0.25 × MIC, ampicillin plus gentamicin was synergistic against 5 of 10 E. gallinarum and all 8 E. casseliflavus, and was bactericidal against 12 of the 18 strains. In contrast, ampicillin plus ceftriaxone was synergistic and bactericidal against only 1 of 10 E. gallinarum and 0 of 8 E. casseliflavus. When the concentration of ampicillin was increased to 10 mg/L, above the MIC for all strains, the combination of ampicillin plus gentamicin was bactericidal against all isolates.
These data suggest that the ampicillin plus gentamicin combination is frequently synergistic and typically bactericidal and may be the preferred treatment option for endovascular infection caused by E. gallinarum or E. casseliflavus. In contrast to the findings for Enterococcus faecalis, ampicillin plus ceftriaxone is generally not synergistic or bactericidal and thus may not be as effective.
鹑鸡肠球菌和格氏肠球菌越来越多地被确认为医疗保健相关感染的病因。尽管肝胆感染和导管相关血流感染占主导,但也可能发生血管内感染。这些感染的最佳治疗方法尚不清楚。
确定氨苄西林、庆大霉素和头孢曲松对鹑鸡肠球菌和格氏肠球菌临床分离株的体外活性。
2008年至2022年期间,在一家机构从不同患者中收集了鹑鸡肠球菌(n = 10)和格氏肠球菌(n = 8)的血流分离株。通过时间杀菌法单独测试氨苄西林的活性,并将其与庆大霉素和头孢曲松联合测试。
所有分离株均对氨苄西林敏感,且无一株庆大霉素MIC>128 mg/L。在0.25×MIC浓度下,氨苄西林加庆大霉素对10株鹑鸡肠球菌中的5株和所有8株格氏肠球菌具有协同作用,对18株菌株中的12株具有杀菌作用。相比之下,氨苄西林加头孢曲松仅对10株鹑鸡肠球菌中的1株和8株格氏肠球菌中的0株具有协同作用和杀菌作用。当氨苄西林浓度增加到10 mg/L(高于所有菌株的MIC)时,氨苄西林加庆大霉素的组合对所有分离株均具有杀菌作用。
这些数据表明,氨苄西林加庆大霉素组合通常具有协同作用且通常具有杀菌作用,可能是鹑鸡肠球菌或格氏肠球菌引起的血管内感染的首选治疗方案。与粪肠球菌的研究结果相反,氨苄西林加头孢曲松通常不具有协同作用或杀菌作用,因此可能效果不佳。